These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 14626985)

  • 41. Off-label marketing and the First Amendment.
    Boumil MM
    N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
    [No Abstract]   [Full Text] [Related]  

  • 42. FDA vs. free speech over drug promotions.
    Anderson C
    Nature; 1991 Dec; 354(6353):421. PubMed ID: 1749421
    [No Abstract]   [Full Text] [Related]  

  • 43. Is it worth the trouble? The new policy on dissemination of information on off-label drug use under the Food and Drug Administration Modernization Act of 1997.
    Weeks EA
    Food Drug Law J; 1999; 54(4):645-65. PubMed ID: 11824459
    [No Abstract]   [Full Text] [Related]  

  • 44. Regulation of dietary supplements: five years of DSHEA.
    Khatcheressian LA
    Food Drug Law J; 1999; 54(4):623-44. PubMed ID: 11824458
    [No Abstract]   [Full Text] [Related]  

  • 45. Prohibited acts and enforcement tools.
    Mathewson NW
    Food Drug Law J; 2010; 65(3):545-54. PubMed ID: 24479241
    [No Abstract]   [Full Text] [Related]  

  • 46. Warner-Lambert found guilty of promoting neurontin off label.
    Larkin M
    Lancet Neurol; 2004 Jul; 3(7):387. PubMed ID: 15228033
    [No Abstract]   [Full Text] [Related]  

  • 47. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 48. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 49. US aims to tighten rules on direct-to-consumer drug ads.
    Vastag B
    Nat Biotechnol; 2007 Mar; 25(3):267. PubMed ID: 17344868
    [No Abstract]   [Full Text] [Related]  

  • 50. Health related claims, the market for information, and the first amendment.
    Beales JH
    Health Matrix Clevel; 2011; 21(1):7-30. PubMed ID: 21847896
    [No Abstract]   [Full Text] [Related]  

  • 51. Courts are arriving at a consensus on Food and Drug Administration speech regulation.
    Samp RA
    Food Drug Law J; 2003; 58(3):313-29. PubMed ID: 14626232
    [No Abstract]   [Full Text] [Related]  

  • 52. Drug firms back-pedal on direct advertising.
    Nature; 2005 Aug; 436(7053):910-1. PubMed ID: 16107811
    [No Abstract]   [Full Text] [Related]  

  • 53. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
    Strawn MN
    J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
    [No Abstract]   [Full Text] [Related]  

  • 54. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
    Berndt ER
    N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
    [No Abstract]   [Full Text] [Related]  

  • 55. The Supreme Court checks out drug promotion restrictions.
    Gilhooley M
    Food Drug Law J; 2003; 58(3):347-52. PubMed ID: 14626982
    [No Abstract]   [Full Text] [Related]  

  • 56. Regulation of dietary supplement advertising: current claims of interest to the Federal Trade Commission, Food and Drug Administration and National Advertising Division.
    Villafranco JE; Lustigman AB
    Food Drug Law J; 2007; 62(4):709-25. PubMed ID: 18557227
    [No Abstract]   [Full Text] [Related]  

  • 57. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 58. The Family Smoking Prevention and Tobacco Control Act and the First Amendment: why a substantial interest in protecting public health won't save some new restrictions on tobacco advertising.
    Stoll E
    Food Drug Law J; 2010; 65(4):873-900, iii. PubMed ID: 24479250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 60. "Daddy, what is erectile dysfunction?" Direct-to-consumer advertising will be changing.
    Feinberg DT
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):866-8. PubMed ID: 16379506
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.